ChronoScale (CHRN) Q3 2025 earnings summary

Executive summary

• Revenue for Q3 2025 increased 2% year-over-year to $4.2 million, rebounding 105% sequentially, driven by higher Enterprise Health device sales in the Americas, partially offset by lower sales in EMEA.

• Gross margin improved to 60.3% from 53% in Q3 2024, reflecting favorable device mix, lower device costs, and improved service margins.

• Net loss for Q3 2025 was $1.4 million, a 31% improvement year-over-year and 48% sequentially.

• Operating expenses declined 19% year-over-year, mainly due to lower payroll and receipt of Employee Retention Credit (ERC).

• Launched eksoUniversity and delivered the first CEU certification.

Financial highlights

• Q3 2025 revenue: $4.2 million (+2% YoY, +105% sequentially); nine-month revenue: $9.7 million (-25% YoY).

• Gross profit for Q3 2025: $2.5 million; gross margin: 60.3%.

• Operating loss for Q3 2025: $1.4 million; net loss per share: $(0.54) (improved from $1.53 in Q3 2024).

• Cash and equivalents at September 30, 2025: $2.7 million, down from $4.5 million at year-end 2024.

• Working capital at quarter-end: $5.9 million, down from $11.3 million at year-end 2024.

Outlook and guidance

• Management expects operating cash requirements to exceed cash provided by operations in the near term.

• Cash is projected to fund operations into Q1 2026; additional financing is being sought.

• Company is exploring strategic transactions, including potential acquisitions or sale of the business.

• Majority of 2025 revenue expected from Enterprise Health, with Personal Health sales ramping up.

• Management remains focused on executing growth strategy and resource management.